Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

William A. Clarke; Etienne Chatelut; Alan K. Fotoohi; Richard A. Larson; Jennifer H. Martin; Ron H.J. Mathijssen; Salvatore J. Salamone

doi:10.1016/j.ejca.2021.08.033

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

William A. Clarke^*
, Etienne Chatelut
, Alan K. Fotoohi
, Richard A. Larson
, Jennifer H. Martin
, Ron H.J. Mathijssen
, Salvatore J. Salamone

^*Corresponding author for this work

Medical Oncology

Johns Hopkins School of Medicine
University of Toulouse
Karolinska University Hospital
The University of Chicago
University of Newcastle
Saladax Biomedical, Inc

Research output: Contribution to journal › Review article › Academic › peer-review

72 Citations (Scopus)

Abstract

Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.

Original language	English
Pages (from-to)	428-440
Number of pages	13
Journal	European Journal of Cancer
Volume	157
DOIs	https://doi.org/10.1016/j.ejca.2021.08.033
Publication status	Published - Nov 2021

Bibliographical note

Funding Information:
The authors thank Jan Beumer, Gareth Veal, Teun van Gelder and Azucena Aldaz Pastor for their helpful comments during the course of finalising the manuscript, as well as the IATDMCT Oncology TDM Scientific Committee for their support of the guideline process.

Publisher Copyright:
© 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2021.08.033Licence: Unspecified

Cite this

Clarke, W. A., Chatelut, E., Fotoohi, A. K., Larson, R. A., Martin, J. H., Mathijssen, R. H. J., & Salamone, S. J. (2021). Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. European Journal of Cancer, 157, 428-440. https://doi.org/10.1016/j.ejca.2021.08.033

@article{6ca714b49dd8489385b9c04d919d7bd4,

title = "Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy",

abstract = "Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.",

author = "Clarke, \{William A.\} and Etienne Chatelut and Fotoohi, \{Alan K.\} and Larson, \{Richard A.\} and Martin, \{Jennifer H.\} and Mathijssen, \{Ron H.J.\} and Salamone, \{Salvatore J.\}",

note = "Funding Information: The authors thank Jan Beumer, Gareth Veal, Teun van Gelder and Azucena Aldaz Pastor for their helpful comments during the course of finalising the manuscript, as well as the IATDMCT Oncology TDM Scientific Committee for their support of the guideline process. Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = nov,

doi = "10.1016/j.ejca.2021.08.033",

language = "English",

volume = "157",

pages = "428--440",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. / Clarke, William A.; Chatelut, Etienne; Fotoohi, Alan K. et al.
In: European Journal of Cancer, Vol. 157, 11.2021, p. 428-440.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Therapeutic drug monitoring in oncology

T2 - International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

AU - Clarke, William A.

AU - Chatelut, Etienne

AU - Fotoohi, Alan K.

AU - Larson, Richard A.

AU - Martin, Jennifer H.

AU - Mathijssen, Ron H.J.

AU - Salamone, Salvatore J.

N1 - Funding Information: The authors thank Jan Beumer, Gareth Veal, Teun van Gelder and Azucena Aldaz Pastor for their helpful comments during the course of finalising the manuscript, as well as the IATDMCT Oncology TDM Scientific Committee for their support of the guideline process. Publisher Copyright: © 2021

PY - 2021/11

Y1 - 2021/11

N2 - Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.

AB - Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.

UR - https://www.scopus.com/pages/publications/85115938008

U2 - 10.1016/j.ejca.2021.08.033

DO - 10.1016/j.ejca.2021.08.033

M3 - Review article

C2 - 34597977

AN - SCOPUS:85115938008

SN - 0959-8049

VL - 157

SP - 428

EP - 440

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this